Sutro Biopharma, Inc. (STRO) community

STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30

$10.26+0.09 (+0.88%)

Close on Nov 11, 2026Market cap $170.12MP/E –Yield –

Community

Notes and questions about Sutro Biopharma from other investors

No posts about STRO yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Sutro Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Dec 3, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is STRO.

Compare: STRO vs CCCC · STRO vs GLUE · STRO vs CHRS · STRO vs RXRX · STRO vs CGEN

Revenue growth-57.3% · median 25.8%

Operating margin-265.0% · median -295.9%

Net margin-344.2% · median -267.8%

Company	Revenue	Growth
GLUE	$70.33M	-61.3%
RXRX	$68.23M	+56.2%
CHRS	$53.64M	+44.4%
STRO	$45.11M	-57.3%
CCCC	$32.28M	+7.2%
CGEN	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 137
Held by institutions: 99.4%
Auditor: Ernst & Young LLP
SEC CIK: 1382101

Advertisement
300 × 250

See a number that looks wrong?